The dopamine D 3 receptor the 'haplotype relative risk' (HRR) design. 8 For HRR, DNA is collected both from the affected individual and (DRD3) Ser 9 Gly from the parents of the affected subject. For the specific locus being tested, the four chromosomes of the parents polymorphism and provide the relevant information to detect linkage or allele effects. The two chromosomes that were transschizophrenia: a haplotype mitted to the affected child are defined as 'disease chromosomes'. The remaining two chromosomes then relative risk study and comprise an ideal control group as they are of the same association with clozapine ethnic origin as the affected individual's chromosomes yet were not transmitted to the ill child. Techniques response such as HRR therefore represent a 'gold standard' for association studies and provide a powerful com- cisely match patients and controls for ethnicity. Conse-and also did not find evidence for an excess of homo- striking difference is our use of the HRR strategy rather Our results suggest that previously reported associations between DRD3 Ser 9 and schizophrenia may have been related to allele frequency differences between excess of DRD3 homozygosity in schizophrenia studies. In the meta-analysis performed by Shaikh and ( 2 = 2.60, P = 0.11).
AK
colleagues, it can be observed that Ser 9 allele frequency The previously reported role of the DRD3 Ser 9 Gly varies in Caucasians from 56% to 71% across studies. polymorphism in clozapine response was tested in 68
As Shaikh et al point out, it is possible that their sigpatients undergoing a double-blind clozapine trial.
nificant association is a result of a relative under-repThere was no significant difference between resentation of Ser 9 in their control population (56%), responders and nonresponders in either genotype or as compared to 64% in the parents of the schizoallele frequency (Table 2 ). There were also no quantiphrenics we studied, and is not due to a cause and tative differences among DRD3 Ser 9 Gly genotypes in effect relationship between Ser 9 and vulnerability for BPRS scores after 10 weeks of clozapine administration schizophrenia. (Figure 1 ). DRD3 genotype also did not significantly Our inability to detect preferential transmission of affect the change in BPRS total score between clozaSer 9 in schizophrenia does not appear to be secondary pine treatment and baseline ratings in these patients to insufficient power. Although our data set is smaller (F(2,65) = 0.53, P = 0.59).
than Shaikh et al, there is no trend toward the observed Therefore, our study finds that the Ser 9 allele of the association and, in fact, there is a non-significant trend D 3 receptor Ser 9 Gly polymorphism was not signifiin the opposite direction (Ser 9 less likely to be passed cantly associated with schizophrenia using a haplotype to the affected offspring). Moreover, power calcurelative risk design with 58 patients. We did not detect lations 9 reveal that our effect size (0.01) would require significant differences in DRD3 Ser 9 Gly allele or genofar greater than 1000 subjects to detect an association type frequencies between patients and their parents at the 0.05 level. Thus a sample size of 133, as in the Shaikh et al study, would not have yielded a significant result. However, if one assumes the effect size of Shaikh et al (0.10), our study group has a power of 0.50 to detect an association and the possibility of Type II error must be considered. Studies with larger HRR data sets may be useful. The HRR design of this study permitted us to compare the DRD3 homozygosity of schizophrenic patients to their parents. Our data are consistent with Shaikh et al and others 10-16 who do not observe an excess of homozygosity at DRD3 Ser 9 Gly in schizophrenia, although we did detect a nonsignificant trend towards homozygosity in patients (62%) as compared to their parents (49%). Power calculation using the effect size of Crocq et al 6 revealed that our study had a power of 0.80 to detect excess homozygosity. It should be noted that implicit in this analysis is the assumption that the frequency of schizophrenia in the parents is substantially lower than the patient group, all of whom are schizophrenic. Although we did not conduct formal psychiatric interviews of the parents, it is a reasonable assumption that the majority of parents are not schizoobservation of an association between the DRD3 Ser 9 allele and clozapine response. phrenic.
An excess of homozygosity at DRD3 Ser 9 Gly in schizophrenia has been reported in some studies.
6,7

Methods
One possibility is that the observed excess homozygosity is an artifact of genotyping. With RFLP, and other Subjects in HRR study Fifty-eight patients (42 M, 16 F, mean age = 35.5 ± 7.1 methods such as single strand conformational polymorphism analysis (SSCP), a heterozygote is identified yrs) meeting DSM-IIIR criteria for schizophrenia or schizoaffective disorder as determined by structured after gel electrophoresis by the presence of two bands (corresponding to the two different alleles on each diagnostic interview (Structured Clinical Interview for DSM-III-R (SCID)) were recruited from the Experichromosome). Each heterozygous DNA band is approximately half the density of the corresponding mental Therapeutics Branch of the National Institute of Mental Health (NIMH) and the Maryland Psychiatric band in homozygotes. Subjects whose genotypes cannot be reliably established may be excluded from
Research Center (MPRC) of the University of Maryland School of Medicine. All gave written informed consent further analyses. Because heterozygotes may be less likely to yield a clear genotype, they may be preferento participate in the study under a protocol approved by the Institutional Review Boards of the NIMH and tially removed, leading to an apparent excess of homozygotes. To avoid this potential artifact of genotyping, the University of Maryland School of Medicine. After obtaining informed consent, the parents of each subject it is critical that reports of excess homozygosity (at any loci) include the total number of DNA samples that were also recruited for genetic testing only. were intended to be genotyped and account for samples in which the genotype could not be estabSubjects in clozapine response study Sixty-eight patients (50 M, 18 F, mean age = 38.4 ± 7.8 lished. In our study, DRD3 genotype was established in all of the patients and in all but one parent, indicatyrs) with schizophrenia or schizoaffective disorder were evaluated for clozapine response. As part of a ing that this potential artifact did not have a significant effect on our results.
double-blind, placebo-controlled study of atypical antipyschotic drug efficacy, Brief Psychiatric Rating Finally, in an overlapping study group of 68 patients, we did not find a significant association between the Scale (BPRS) ratings were obtained after clinical stabilization on typical neuroleptic for at least 4 weeks DRD3 Ser 9 Gly polymorphism and the antipsychotic response to clozapine. These data contrast with the (mean dose in CPZ equivalents = 1019 ± 497 mg day −1 ) and then after 10 weeks of clozapine treatment (mean Shaikh et al report of an association between the Ser 9 /Ser 9 genotype and failure to respond to clozapine. dose = 408 ± 116 mg day
) by raters blind to treatment status. Clozapine responders demonstrated at least a Our inability to replicate this association could be related to several factors. A remote possibility is that a 20% reduction in BPRS total score. We also examined the relationship of DRD3 Ser 9 Gly genotype to BPRS different D 3 receptor polymorphism may be in linkage disequilibrium with Ser 9 in European Caucasian scores after 10 weeks of clozapine treatment. patients but not in US patients. However, at present, no other DRD3 variant has been identified that could DNA analysis Venous blood samples were anticoagulated with acid explain the previously observed association and there is no reason to believe that our population is substancitrate dextrose solution. Genomic DNA was extracted from peripheral lymphocytes using standard protocols. tially divergent genetically. Second, the difference in clozapine response rate (28% in our group vs 59% in DNA was amplified by polymerase chain reaction (PCR) with primers flanking exon 1 of the DRD3 gene. the European Caucasian group) should be noted. A 28% response rate is consistent with previous doubleThe sense primer sequence was 5′-GCT CTA TCT CCA ACT CTC ACA-3′ and the anti-sense sequence was 5′-blind studies of clozapine's efficacy in chronic schizophrenia.
17,18 These differences in clozapine response AAG TCT ACT CAC CTC CAG GTA-3′. The PCR reaction was carried out in a 10-l reaction volume with rate may be secondary to different rating scales, our double-blind methodology, or our use of a stan-400 ng DNA, 250 nM of each primer, 50 nM of each dNTP (dATP, dGTP, dCTP, and dTTP), 0.5 l Taq polydardized typical neuroleptic control period to establish clozapine response. Third, the Shaikh et al study group merase (Perkin Elmer Cetus; AmpliTaq, Norwalk, CT, USA), 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 0.01% is larger than ours and therefore our study has less power (Ͻ0.50 based on the Shaikh et al effect size) to gelatin and 0.5 mM dithiothreitol in a Perkin Elmer Cetus 9600 thermal cycler. Following an initial denatdetect an association of modest effect. Because our non-significant trend is in the same direction as that uration phase at 95°C for 5 min, 35 amplification cycles were performed: 92°C for 30 s, 56°C for 30 s, 72°C for observed by Shaikh et al, further study of the role of Ser 9 Gly in clozapine response may be warranted. 30 s, followed by a 72°C phase for 10 min. The BalI isoschizomer MscI (New England Biolabs, In conclusion, we fail to replicate the previous report of an association between the DRD3 Ser 9 allele with Beverly, MA, USA) was added to the PCR product in the following proportions: a 5-l cocktail consisting of schizophrenia in an HRR study. Moreover, we do not observe an excess of homozygosity at this locus in 1 l MscI (3 units l −1 ), 1.5 l of NE-4 buffer (New England Biolabs), and 2.5 l H 2 O was added to the 10-schizophrenia. Finally, we are unable to confirm the
